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A B S T R A C T
Several studies have been performed investigating the role of a real-time multiplex polymerase chain reaction assay
LightCycler® SeptiFast® with inconsistent results. In prospective evaluation of adult patients with severe sepsis or septic
shock SeptiFast assay and blood culture results were compared regarding concordance, the impact of SeptiFast assay on
antimicrobial therapy adjustment, time to results and the role of SeptiFast assay as a marker of disease severity. 63 blood
sample sets were collected from 57 patients. 51 (80.9%) results were concordant negative and 7 (11.1%) concordant posi-
tive. In one (1.6%) sample set blood culture was positive and SeptiFast assay negative, in three (4.8%) sample sets with
negative blood cultures pathogens were detected by SeptiFast assay and in one (1.6%) patient an additional pathogen was
detected by SeptiFast assay. If blood culture is considered as »gold standard«, 1 (1.6%) SeptiFast false negative and 4
(6.3%) false positive results were identified (sensitivity 87.5%, specificity 92.6%, negative predictive value 97.8%). Antibi-
otic treatment was adjusted according to SeptiFast assay in 4 (6.3%) cases. Time to final results was significantly shorter
with SeptiFast assay (32±23 h vs. 97±28 h, p<0.0001). Positive SeptiFast assay was not associated with higher mortal-
ity, C-reactive protein or procalcitonin (p=0.74, p=0.44 and p=0.12, respectively). According to our results SeptiFast as-
say can be used as a valuable add-on to blood culture in diagnostic workup of patients with severe sepsis and septic shock
but it cannot replace the blood culture.
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Introduction
Numerous studies have been performed investigating
the role and usefulness of a commercially available real-
-time multiplex polymerase chain reaction (PCR) assay
LightCycler® SeptiFast® (SF) which can detect 25 of the
most important sepsis pathogens in the management of
patients with sepsis1–9. These studies were performed in
different settings, including surgical and medical inten-
sive care patients, pediatric, hematology and cancer pa-
tients. Patients with suspected sepsis as well as severe
sepsis or septic shock have been recruited1–9. The role of
SF as marker of disease severity has been investigated as
well, introducing the concept of »DNAemia« in to the
treatment of sepsis10,11.
In spite of inconsistent results SF assay remains at-
tractive due to shorter time to results in comparison to
blood cultures (BC) and consecutive possibility for faster
adjustment of antibiotic therapy1,11. There is little infor-
mation on the use of SF assay in population of adult med-
ical patients with severe sepsis or septic shock and no ex-
perience of use of SF assay in Slovenia. SF assay and BC
results were compared, time to results and the impact of
SF assay results on adjustment of antimicrobial therapy
in patients with severe sepsis and septic shock were ana-
lyzed and the role of positive SF assay as a possible
marker of disease severity was studied.
Patients and Methods
This prospective study was conducted in the 12-bed
Medical Intensive Care Unit (ICU) at University Medical
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Centre Maribor from September 2011 to September
2012. Adult patients who fulfilled the criteria for severe
sepsis or septic shock12 were included. In all patients
blood samples for BC and SF assay were taken before
empiric antibiotic therapy was initiated. One set of man-
datory microbiology samples consisted of a paired collec-
tion of BC (one aerobic and one anaerobic bottle from
two sites, at least one was from peripheral veins) and 5
ml of EDTA blood for SF assay taken from the same pe-
ripheral vein as for BC. Microbiology samples from other
body sites were collected when clinically indicated.
For BC 20 mL of blood were collected and 10 mL inoc-
ulated in each of aerobic and anaerobic BacT/Alert FAN
bottle (bioMerieux, Marcy l’Etoile, France). Inoculated
BC bottles and blood samples for SF assay were trans-
ported to microbiology department (which is located ap-
proximately 4 km away from ICU) on the same day if
samples were taken before 6 p.m. or next day if samples
were taken after 6 p.m. SF samples were stored at 4 °C if
immediate analysis was not possible.
In the microbiology laboratory BC bottles were incu-
bated for a total of 5 days at 37 °C in the BacT/Alert 3D
automated BC system (bioMerieux, Marcy l’Etoile, Fran-
ce). All BC bottles signaled as positive were processed ac-
cording to standard microbiology laboratory procedures.
Blood samples for SF assay (Roche Diagnostics, Mann-
heim, Germany) were processed strictly following manu-
facturer’s instructions13.
Positive BC (Gram stain, isolated pathogen and anti-
biotic resistance) were reported to the attending physi-
cian by telephone as soon as available. SF assay was per-
formed from 8 a.m. to 4 p.m. on weekdays and from 8
a.m. to 1 p.m. on Saturdays. The results were reported as
soon as possible to the attending physician.
Clinical data including age, gender, APACHE II score
(Acute Physiology and Chronic Health Evaluation II),
ICU and hospital length of stay, laboratory results and
concomitant or previous (within 48 h) antibiotic treat-
ment. Complications during sample withdrawal, in-hos-
pital storage, transportation to laboratory and sample
analysis were recorded and documented.
The study was approved by the National Medical Eth-
ics Committee of the Republic of Slovenia (Number 130/
09/07) and informed consent was obtained from all pa-
tients being included in the study.
McNemar test was used to compare blood culture and
SF results. The relationship between positive SF test and
mortality was tested using the Fisher’s exact test. P-
value <0.05 was regarded as statistically significant.
Results
In all, 63 sets comprising 2 aerobic BC bottles, 2 an-
aerobic BC bottles and one blood sample for SF assay
were taken from 57 patients (19 female and 38 male,
mean age 59.5±14.8 years). Two sets of samples were
taken from 6 (11.3%) patients. In-hospital mortality was
52.6%. In-hospital length of stay was 27±28.9 days.
Mean admission APACHE II score was 25±7.6. At the
time when samples were taken for BC and SF assay 39
(61.9%) patients had received antibiotic therapy.
In 51 (80.9%) sample sets both methods – BC and SF
assay – showed concordant negative results. BC and SF
assay were concordantly positive in seven sample sets
(Table). In one sample set BC was positive whereas the
SF assay yielded negative result (Table, patient No 2). In
three sample sets with negative BC pathogens were de-
tected by SF assay (Table, patient No 3, 6, 7) and in one
set an additional pathogen was detected by SF assay (Ta-
ble, patient No 10). If we consider BC as »gold standard«,
then 1 (1.6%) SF false negative result and 4 (6.3%) SF
false positive results were identified (SF sensitivity
87.5%, specificity 92.6%, positive predictive value 66.4%,
and negative predictive value 97.8%). There was no sta-
tistically significant difference between SF and BC tests
regarding concordance of results (c2(1)=0.80, p=0.37).
No pathogens were detected by BC that are not included
in the SF assay detection list.
In 6 patients 2 sets of BC and SF samples were col-
lected. In one of those patients (Table, patient No 10) BC
and SF were positive in samples collected on the first day
and day 29 of ICU treatment. In the sample set collected
on the first day SF was positive for Enterobacter cloacae/
aerogenes and Escherichia coli, while Enterobacter cloa-
cae only was isolated from BC. On day 29 SF was positive
for E. cloacae/aerogenes and E. cloacae was isolated from
BC (Table 1, patient No. 10*). In the remaining five pa-
tients the results were concordantly negative.
In patients with discordant results microbiological
samples obtained on the same day from different sites
(tracheal aspirate, urine, wound swabs, catheter tips or
other) were checked. In 2 (3.2%) cases Streptococcus
pneumoniae was detected by SF and in tracheal aspirates
(Table 1, patients No. 6 and 7). Thus both SF results can
be interpreted as true positive.
Three patients with positive SF and negative BC (Ta-
ble, patients No 3, 6 and 7) received antibiotics at the
time when samples were taken or within previous 48 h.
In one case coagulase negative staphylococci (Staphylo-
coccus epidermidis) were isolated by BC, SF was nega-
tive. The same pathogen was isolated on central venous
catheter tip and from two BC collected from peripheral
vein. In one case a polymicrobial infection was detected
by SF (E. cloacae/aerogenes, E. coli) while E. cloacae only
was isolated from BC and tracheal aspirate (Table 1, pa-
tient No. 10).
Antibiotic treatment was adjusted according to re-
sults of SF assay in 4 (6.3%) cases. In 3 cases antibiotic
was added (cloxacillin for Staphylococcus aureus, vanco-
mycin for S. aureus and ertapenem for E. coli), in 1 case
antibiotic was discontinued (azithromycin for S. pneu-
moniae) (Table 1). A nonsignificant decrease in both
C-reactive protein (CRP) and procalcitonin levels after
48 h was observed in cases of antibiotic change (153±43
mg/L vs. 111±11 mg/L, p=0.11 for CRP and 15.9±16.7
ng/mL vs. 2.6±2.4, p=0.24 ng/mL for procalcitonin).
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First information regarding positive BC (Gram stain
result from positive BC bottle) was obtained in 21±7 h,
and time to final blood culture result was 97±28 h. SF
results were obtained in 32±23 h. Time to final result
was significantly shorter with SF assay (p<0.0001). The
difference between time to first information regarding
positive BC and SF result did not reach statistical signifi-
cance (p=0.16).
Positive SF results were not associated with higher
APACHE II scores (25.1±7.9 vs. 25.2±7.6, p=0.97) or
with increased mortality (55.5 vs. 52.1 %, p=0.74). Posi-
tive SF results were also not associated with higher CRP
or procalcitonin levels (151±38 mg/L vs. 164±50 mg/L,
p=0.44 and 15.6±15.6 ng/mL vs. 8.2±12.6 ng/mL, p=
0.12, respectively).
A limited evaluation of financial impact of introduc-
ing SF assay to management of patients with severe sep-
sis or septic shock was performed using a set price of 150
EUR per SF assay for material costs only10. Sixty-three
SF assays were performed, costing approximately 9500
EUR. The estimated cost of detecting one positive SF re-
sult was approximately 950 EUR.
Discussion
In the first Slovenian evaluation of the usefulness of
SF assay in adult patients with severe sepsis or septic
shock the results were comparable to other studies. Both
sensitivity and specificity of SF assay in our study were
located in the upper range of previously reported data
(87.5% and 92.6%, respectively)1–8. Our results are in line
with the recent metaanalysis, which highlighted the role
of SF as rule-in tool for early detection of septic patients8.
The rate of pathogens detected by SF and not by BC
(6.3%) as well as the rate detected by BC and not by SF
(1.6%) was lower compared to other studies. The main
reason for these lower rates might be perhaps a relatively
low number of patients included in the study. In two pa-
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TABLE 1
SEPTIFAST ASSAY AND BLOOD CULTURE POSITVE CASES
Patient
Number













































No change 46 138 Survived







Vancomycin 16 56 (16) Survived
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No change 42 72 (24) Survived





Meropenem No change 30 48 (24) Survived
SF – SeptiFast assay, BC – blood cultures, TA – tracheal aspirates, CVC – central venous catheter, * a second set of samples withdrawn
from the same patient 29 days later
tients an identical pathogen (S. pneumoniae) was identi-
fied in tracheal aspirates, which suggests a true positive
result. Results of several studies assessing the diagnostic
utility of the real-time PCR for S. pneumoniae in blood
and respiratory samples for the diagnosis of pneumo-
coccal pneumonia indicated that real-time PCR performs
better than culture14. In three patients with positive SF
result negative BC can be explained by antibiotic treat-
ment at the time of sample collection.
Some previous reports showed that detection of pa-
thogen DNA is associated with higher organ dysfunction
scores and points to higher mortality10,15. Positive SF test
has also been associated with higher levels of inflamma-
tory markers10. In contrast, in our study positive SF re-
sult was not associated with either mortality or higher
APACHE II scores.
Rapid institution of appropriate antibiotic therapy is
important in treating patients with sepsis16,17. Initial se-
lection of antibiotic therapy is usually empiric12. Even
though broad-spectrum antibiotics are used as empiric
therapy12,16,17, changes of antibiotic therapy or additional
antimicrobial agents are needed in 40–60% of patients
once a pathogen is isolated18. In this study antibiotic
treatment was adjusted according to results of SF assay
in 4 (6.3%) cases. In 3 cases an antibiotic was added and
in one case antibiotic was discontinued. In all cases the
decision to alter antibiotic therapy was considered with
regard to the clinical state and laboratory results of the
patients at that time. A decrease in inflammatory mark-
ers may suggest a correct decision8. Administration of in-
adequate antimicrobial treatment to critically ill is asso-
ciated with greater mortality when compared to ade-
quately treated patients19 and change of antibiotic later
in the course of treatment seems not to lower mor-
tality20. These studies were performed using standard
microbiology methods. In other studies, antibiotic treat-
ment adjustment would have been needed in about 10%
of SF results2–5,10.
Introduction of SF assay into routine clinical manage-
ment is complex. The advantage of shorter turnaround
time of SF assay in comparison to BC is optimal when the
assay is performed on a daily basis and immediately after
sample collection. That was not the case in our study, re-
sulting in preliminary BC results being obtained faster
than SF results. However, even with SF analysis not per-
formed on Saturday afternoons and Sundays, a signifi-
cant time benefit was present when comparing final re-
sults. In order to take full advantage of shorter SF
analysis, it would probably make sense to have a dedi-
cated team responsible only for SF analysis, and not to
impose SF analysis to a system that has been developed
around the needs of a standard method21, as was the case
in our study. However, such an approach would result in
higher cost of SF assay.
Shorter SF assay turnaround times facilitate early,
targeted antibiotic treatment, possibly resulting in use of
fewer antibiotics and lower total ICU treatment costs.
Economic saving afforded by the use of the PCR assay
has been demonstrated in septic shock patients22 and in
patients with candidemia23. Because of a relatively small
patient cohort we only performed a limited evaluation of
financial impact of introduction of SF assay to clinical
practice. High cost of ICU treatment itself reduces the fi-
nancial impact of SF test.
Other PCR based techniques (e.g. VYOO®, SIRS-Lab
GmbH, Jena, Germany and SepsiTest™, Molzym, Bre-
men, Germany) are being tested with roughly similar
results24,25. Additionally, other approaches which signifi-
cantly shorten the time to identify causative agent of sep-
sis, such as matrix-assisted laser desorption/ionisation-
-time of flight (MALDI-TOF) mass spectrometry and
fluorescence in situ hybridization (FISH). These tech-
niques enable rapid identification of pathogens, however,
do not shorten the time to susceptibility testing result22.
According to the results of our study SF assay can be
used as a valuable add-on to conventional blood culture
in diagnostic workup of patients with severe sepsis and
septic shock but it cannot replace the blood culture.
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SEPTIFAST PCR TEST ZA OTKRIVANJE UZRO^NIKA U BOLESNIKA S
TE[KOM SEPSOM ILI SEPTI^KIM [OKOM
S A @ E T A K
Mnoge studije, koje su istra`ivale ulogu polimerazne lan~ane reakcije LightCycler® SeptiFast®, su pokazale nedo-
sljedne rezultate. U prospektivnoj procjeni odraslih bolesnika s te{kom sepsom ili septi~kim {okom istra`ivali smo:
uskla|enost rezultata SeptiFast testa i hemokultura, utjecaj SeptiFast testa na prilagodbu antimikrobne terapije, vrije-
me do rezultata SeptiFast testa i ulogu SeptiFast testa kao pokazatelja te`ine bolesti. Prikupili smo 63 krvna uzorka od
57 bolesnika. 51 rezultat (80,9%) je bio uskla|en negativno, a 7 rezultata (11,1%) je bilo uskla|eno pozitivno. U jednom
uzorku (1,6%) su hemokulture bile pozitivne, a SeptiFast test negativan. U tri uzorka (4,8%) s negativnim hemokul-
turama je SeptiFast test bio pozitivan. U jednog bolesnika (1,6%) smo SeptiFast testom otkrili dodatnog uzro~nika. Ako
se hemokulture smatraju »zlatnim standardom«, dobili smo 1 (1,6%) SeptiFast la`no negativan rezultat i 4 (6,3%)
SeptiFast la`no pozitivna rezultata (osjetljivost 87,5%, specifi~nost 92,6%, negativna prognosti~ka vrijednost 97,8%). U
4 (6,3%) primjera je antibioti~ka terapija bila prilago|ena rezultatu SeptiFast testa. Vrijeme do kona~nog rezultata je
bilo signifikantno kra}e s SeptiFast testom (32±23 h vs. 97±28 h, p<0,0001). Pozitivan SeptiFast test nije bio povezan s
vi{im mortalitetom (p=0,74), vi{im C-reaktivnim proteinom (p=0,44) ili vi{im prokalcitoninom (p=0,12). Prema na{im
rezultatima, SeptiFast test se mo`e koristiti kao vrijedan dodatak hemokulturama u dijagnosti~koj obradi bolesnika s
te{kom sepsom i septi~kim {okom, ali ne mo`e zamijeniti hemokulture.
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